DAS Therapeutics is a privately funded clinical stage pharmaceutical company.
The mission of DAS is to identify, acquire and develop unique assets for conditions overlooked or under-served by current treatment approaches to improve patient outcomes.
Our first company, DAS-MG, has an innovative combination therapy (DAS-001) for treating the symptoms of Myasthenia Gravis.
Myasthenia gravis is a debilitating, chronic autoimmune disease of the neuromuscular junction affecting a person’s muscle strength and ability to function. Current treatment options may cause side effects that lead to significant tolerability issues. DAS-001 is a proposed fixed-dose combination tablet that combines the gold standard first-line treatment, pyridostigmine, with an antagonist of the gastrointestinal side effects of pyridostigmine.
A successful Phase 1 study was completed in healthy volunteers and we have begun Phase 2 clinical trial enrollment.
Read the press release
To learn more about DAS-MG or discuss partnership opportunities, please contact us at:
312-508-0101 or inforequest@dastherapeutics.com